The effect of COVID-19 vaccination on the risk of persistent post COVID-19 condition: Cohort study

Abstract

We conducted a population-based cohort study in Stockholm, Sweden, to investigate the effect of COVID-19 vaccination on the risk of developing persistent PCC in individuals surviving the first year after a SARS-CoV-2 infection. 331,042 individuals were included, of which 852 had persistent PCC. The adjusted RR (95% CI) for developing persistent PCC compared with unvaccinated individuals was 0.81 (0.59-1.10) for 1 dose, 0.42 (0.35-0.52) for 2 doses, and 0.37 (0.27-0.52) for three doses. Reduced risks for vaccinated individuals were also observed when restricting the analyses to pre-Omicron and Omicron, as well as all subgroups including sex, age, and previous infection.